These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38409069)

  • 1. Systemic immune-inflammation index and in-stent restenosis in patients with acute coronary syndrome: a single-center retrospective study.
    Xie F; Yu Z; Xiong Y; Wu Z; Wu Y
    Eur J Med Res; 2024 Feb; 29(1):145. PubMed ID: 38409069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents.
    Zhu Y; Liu K; Chen M; Liu Y; Gao A; Hu C; Li H; Zhu H; Han H; Zhang J; Zhao Y
    Cardiovasc Diabetol; 2021 Jul; 20(1):137. PubMed ID: 34238294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atherogenic Index of Plasma and the Risk of In-Stent Restenosis in Patients with Acute Coronary Syndrome beyond the Traditional Risk Factors.
    Zhu Y; Chen M; Liu K; Gao A; Kong X; Liu Y; Han H; Li H; Zhu H; Zhang J; Zhao Y
    J Atheroscler Thromb; 2022 Aug; 29(8):1226-1235. PubMed ID: 34497172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic immune inflammation index and its implication on in-stent restenosis among patients with acute coronary syndrome.
    Ösken A; Polat F; Çakir B; Zengin A; Çalik AN; Ünal Dayi Ş; Çam N
    Coron Artery Dis; 2024 May; 35(3):209-214. PubMed ID: 38180335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and risk factors of in-stent restenosis after percutaneous coronary intervention in patients from southern China.
    Li M; Hou J; Gu X; Weng R; Zhong Z; Liu S
    Eur J Med Res; 2022 Jan; 27(1):12. PubMed ID: 35065663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive Value Analysis of in-Stent Restenosis Within Three Years in Older Acute Coronary Syndrome Patients: A Two-Center Retrospective Study.
    Zhou J; Chai D; Dai Y; Wang A; Yan T; Lu S
    Clin Appl Thromb Hemost; 2022; 28():10760296221107888. PubMed ID: 35706375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis.
    Zeng M; Yan X; Wu W
    BMC Cardiovasc Disord; 2021 Sep; 21(1):446. PubMed ID: 34535088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of serum apoA-I with in-stent restenosis in coronary heart disease.
    Wang X; Zhang M; Cheng J; Zhou H
    BMC Cardiovasc Disord; 2022 Aug; 22(1):355. PubMed ID: 35927634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Prediction Model Construction of Drug-Coated Balloon Combined with Cutting Balloon Angioplasty in the Treatment of Drug-Eluting Stent In-Stent Restenosis.
    Wu H; Yu T; Fan T; Liao W
    Comput Math Methods Med; 2022; 2022():9832622. PubMed ID: 36238492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of outcomes after treatment of in-stent restenosis using newer generation drug-eluting stents versus drug-eluting balloon: Patient-level pooled analysis of Korean Multicenter in-Stent Restenosis Registry.
    Lee JM; Rhee TM; Hahn JY; Hwang D; Park J; Park KW; Kim HL; Kim SH; Chae IH; Doh JH; Jeon KH; Choi YJ; Park JS; Choi SH; Gwon HC; Koo BK; Alfonso F; Kim HS
    Int J Cardiol; 2017 Mar; 230():181-190. PubMed ID: 28043660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of increased serum CTRP5 levels with in-stent restenosis after coronary drug-eluting stent implantation: CTRP5 promoting inflammation, migration and proliferation in vascular smooth muscle cells.
    Shen Y; Li C; Zhang RY; Zhang Q; Shen WF; Ding FH; Lu L
    Int J Cardiol; 2017 Feb; 228():129-136. PubMed ID: 27863353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of peripheral blood eosinophil count in predicting in-stent restenosis in patients with stable angina pectoris undergoing drug eluting stenting.
    Hajizadeh R; Ghaffari S; Separham A; Shokouhi B; Kavandi H; Pourafkari L; Nader ND
    Rom J Intern Med; 2017 Dec; 55(4):229-236. PubMed ID: 28672766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI.
    Song T; Fu Y; Wang Y; Li W; Zhao J; Wang X; Wang H; Zhao Y; Fu X
    BMC Cardiovasc Disord; 2021 Jan; 21(1):24. PubMed ID: 33413149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between fibrinogen-to-albumin ratio and in-stent restenosis in patients with coronary artery disease undergoing drug-eluting stenting.
    Chen T; Sun JL; Zhang J
    Coron Artery Dis; 2020 Nov; 31(7):586-589. PubMed ID: 32271235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of red blood cell distribution in predicting drug-eluting stent restenosis in patients with stable angina pectoris after coronary stenting.
    Zhao K; Li YJ; Gao S
    Coron Artery Dis; 2015 May; 26(3):220-4. PubMed ID: 25647458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Derivation and validation of the ISAR score to predict the risk of repeat percutaneous coronary intervention for recurrent drug-eluting stent restenosis.
    Coughlan JJ; Aytekin A; Lahu S; Scalamogna M; Wiebe J; Pinieck S; Kufner S; Xhepa E; Joner M; Kuna C; Voll F; Laugwitz KL; Schunkert H; Kastrati A; Cassese S
    EuroIntervention; 2023 Apr; 18(16):e1328-e1338. PubMed ID: 36785947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis.
    Nojima Y; Yasuoka Y; Kume K; Adachi H; Hattori S; Matsutera R; Kohama Y; Sasaki T
    Coron Artery Dis; 2014 Dec; 25(8):638-44. PubMed ID: 25076360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
    Almalla M; Pross V; Marx N; Hoffmann R
    Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome of percutaneous treatment of in-stent restenosis with drug-eluting stents: results from the first phase of the prospective multicentre German DES.DE registry.
    Abdel-Wahab M; Nienaber CA; Mostafa AE; Sabin G; Tebbe U; Hochadel M; Senges J; Akin I; Kuck KH; Hamm C; Richardt G;
    EuroIntervention; 2011 Jun; 7(2):201-8. PubMed ID: 21646062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.